

- 34) Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. *J Thromb Haemost* 2016; **14**: 1308-13.
- 35) Reilly PA, Lehr T, Haertter S, et al. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol* 2014; **63**: 321-8.
- 36) Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. *Thromb Haemost* 2010; **104**: 633-41.
- 37) European Medicine Agency. Annex I. Dabigatran summary of product characteristics. Available at: <http://www.ema.europa.eu/>. Accessed on 30/03/2017.
- 38) European Medicine Agency. Annex I. Rivaroxaban summary of product characteristics. Available at: <http://www.ema.europa.eu/>. Accessed on 30/03/2017.
- 39) European Medicine Agency. Annex I. Apixaban summary of product characteristics. Available at: <http://www.ema.europa.eu/>. Accessed on 30/03/2017.
- 40) European Medicine Agency. Annex I. Edoxaban summary of product characteristics. Available at: <http://www.ema.europa.eu/>. Accessed on 30/03/2017.
- 41) Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015; **385**: 2288-95.
- 42) Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. *Thromb Haemost* 2011; **106**: 156-64.
- 43) Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. *Am J Clin Pathol* 2013; **139**: 102-9.
- 44) Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. *Pathology* 2016; **48**: 60-71.
- 45) Oxha A, Banzato A, Ruffatti A, Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. *Autoimmun Rev* 2017; **16**: 173-8.
- 46) van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. *J Thromb Haemost* 2011; **9**: 1657-9.
- 47) Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. *Semin Thromb Hemost* 2014; **40**: 163-71.
- 48) Krilis SA, Giannakopoulos B. Laboratory methods to detect antiphospholipid antibodies. *Hematology Am Soc Hematol Educ Program* 2014; **2014**: 321-8.
- 49) Halbmayr WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. *Clin Chem Lab Med* 2012; **50**: 1601-5.

Arrived: 4 May 2017 - Revision accepted: 13 July 2017

Correspondence: Armando Tripodi

"Angelo Bianchi Bonomi" Haemophilia and Thrombosis Centre

Via Pace

20132 Milano, Italy

e-mail: armando.tripodi@unimi.it



SIMTI SERVIZI SPA